Bridge City Capital LLC Buys 18,511 Shares of Nutex Health Inc. $NUTX

Key Points

• Bridge City Capital acquired 18,511 Nutex Health shares worth approximately $3.9 million, giving it a 0.27% stake. Hedge funds and institutional investors collectively own 5.32% of the company.
• Analyst sentiment is largely positive: four analysts rate Nutex Health a Buy and one rates it Hold, producing a consensus “Moderate Buy” rating and an average price target of $323.67.
• Nutex Health reported quarterly EPS of $9.38, exceeding the $4.95 consensus estimate, while revenue reached $210.75 million. Shares opened at $200.15, compared with a 52-week range of $83.99 to $226.16.

Bridge City Capital LLC purchased a new stake in shares of Nutex Health Inc. (NASDAQ:NUTX - Free Report) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor purchased 18,511 shares of the company's stock, valued at approximately $3,918,000. Bridge City Capital LLC owned about 0.27% of Nutex Health at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. BlackRock Inc. acquired a new position in Nutex Health in the 2nd quarter worth about $69,612,000. Winmill & CO. Inc. purchased a new position in Nutex Health in the second quarter worth $11,168,000. Empowered Funds LLC purchased a new position in Nutex Health during the 2nd quarter valued at about $7,720,000. Bank of New York Mellon Corp purchased a new position in shares of Nutex Health during the second quarter valued at approximately $3,956,000. Finally, Smith Group Asset Management LLC acquired a new position in Nutex Health in the first quarter valued at $1,244,000. 5.32% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Nutex Health news, Director Scott Saunders sold 203 shares of the business's stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $214.25, for a total transaction of $43,492.75. Following the sale, the director directly owned 400 shares in the company, valued at approximately $85,700. The trade was a 33.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 44.68% of the company's stock.

Analyst Upgrades and Downgrades

NUTX has been the topic of a number of research analyst reports. Wall Street Zen lowered Nutex Health from a "buy" rating to a "hold" rating in a report on Saturday. Lake Street Capital reaffirmed a "buy" rating and issued a $310.00 price target (up from $235.00) on shares of Nutex Health in a research note on Tuesday, August 11th. Weiss Ratings upgraded shares of Nutex Health from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Tuesday, October 6th. LADENBURG THALM/SH SH began coverage on shares of Nutex Health in a research report on Monday, October 26th. They set a "buy" rating and a $336.00 target price for the company. Finally, B. Riley Financial restated a "buy" rating on shares of Nutex Health in a research note on Friday, September 4th. Four investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $323.67.

Nutex Health Stock Performance

Shares of NUTX opened at $200.15 on Monday. The firm has a market capitalization of $1.37 billion, a price-to-earnings ratio of 7.86 and a beta of 0.66. The company has a debt-to-equity ratio of 0.59, a current ratio of 5.00 and a quick ratio of 4.96. Nutex Health Inc. has a 1-year low of $83.99 and a 1-year high of $226.16. The company has a 50-day moving average of $203.24 and a 200 day moving average of $150.70.

Nutex Health (NASDAQ:NUTX - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported $9.38 earnings per share for the quarter, topping analysts' consensus estimates of $4.95 by $4.43. Nutex Health had a net margin of 21.25% and a return on equity of 39.74%. The business had revenue of $210.75 million during the quarter, compared to the consensus estimate of $215.03 million. On average, research analysts expect that Nutex Health Inc. will post 26.65 EPS for the current year.

Nutex Health Profile

Nutex Health, Inc NASDAQ: NUTX is a physician-led healthcare services company that operates an integrated network of hospitals, medical facilities and physician practices in the United States. The company focuses on providing convenient, community-based care through its micro-hospitals and other healthcare locations.

Its hospital operations generally include emergency services, inpatient care, diagnostic testing and outpatient treatment. Nutex also operates physician networks and supports primary care and specialty providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.